These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 23211569)

  • 1. The interfaces between signal transduction pathways: IGF-1/mTor, p53 and the Parkinson Disease pathway.
    Levine AJ; Harris CR; Puzio-Kuter AM
    Oncotarget; 2012 Nov; 3(11):1301-7. PubMed ID: 23211569
    [No Abstract]   [Full Text] [Related]  

  • 2. The regulation of AMPK beta1, TSC2, and PTEN expression by p53: stress, cell and tissue specificity, and the role of these gene products in modulating the IGF-1-AKT-mTOR pathways.
    Feng Z; Hu W; de Stanchina E; Teresky AK; Jin S; Lowe S; Levine AJ
    Cancer Res; 2007 Apr; 67(7):3043-53. PubMed ID: 17409411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The regulation of energy metabolism and the IGF-1/mTOR pathways by the p53 protein.
    Feng Z; Levine AJ
    Trends Cell Biol; 2010 Jul; 20(7):427-34. PubMed ID: 20399660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The tumor suppressor p53: cancer and aging.
    Feng Z; Hu W; Rajagopal G; Levine AJ
    Cell Cycle; 2008 Apr; 7(7):842-7. PubMed ID: 18414039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p53 regulation of the IGF-1/AKT/mTOR pathways and the endosomal compartment.
    Feng Z
    Cold Spring Harb Perspect Biol; 2010 Feb; 2(2):a001057. PubMed ID: 20182617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conservative growth hormone/IGF-1 and mTOR signaling pathways as a target for aging and cancer prevention: do we really have an antiaging drug?
    Anisimov VN
    Interdiscip Top Gerontol; 2015; 40():177-88. PubMed ID: 25341521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ataxia telangiectasia mutated impacts insulin-like growth factor 1 signalling in skeletal muscle.
    Ching JK; Luebbert SH; Collins RL; Zhang Z; Marupudi N; Banerjee S; Hurd RD; Ralston L; Fisher JS
    Exp Physiol; 2013 Feb; 98(2):526-35. PubMed ID: 22941977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Be quiet and you'll keep young: does mTOR underlie p53 action in protecting against senescence by favoring quiescence?
    Dulic V
    Aging (Albany NY); 2011 Jan; 3(1):3-4. PubMed ID: 21248373
    [No Abstract]   [Full Text] [Related]  

  • 9. Tissue-specific responses of IGF-1/insulin and mTOR signaling in calorie restricted rats.
    Sharma N; Castorena CM; Cartee GD
    PLoS One; 2012; 7(6):e38835. PubMed ID: 22701721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Caloric restriction: is mammalian life extension linked to p53?
    Tucci P
    Aging (Albany NY); 2012 Aug; 4(8):525-34. PubMed ID: 22983298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin-like growth factor-1 signaling in renal cell carcinoma.
    Tracz AF; Szczylik C; Porta C; Czarnecka AM
    BMC Cancer; 2016 Jul; 16():453. PubMed ID: 27405474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dysregulation of the IGF-I/PI3K/AKT/mTOR signaling pathway in autism spectrum disorders.
    Chen J; Alberts I; Li X
    Int J Dev Neurosci; 2014 Jun; 35():35-41. PubMed ID: 24662006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miR-199a-3p is involved in estrogen-mediated autophagy through the IGF-1/mTOR pathway in osteocyte-like MLO-Y4 cells.
    Fu J; Hao L; Tian Y; Liu Y; Gu Y; Wu J
    J Cell Physiol; 2018 Mar; 233(3):2292-2303. PubMed ID: 28708244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin-like growth factor 1 can promote proliferation and osteogenic differentiation of human dental pulp stem cells via mTOR pathway.
    Feng X; Huang D; Lu X; Feng G; Xing J; Lu J; Xu K; Xia W; Meng Y; Tao T; Li L; Gu Z
    Dev Growth Differ; 2014 Dec; 56(9):615-24. PubMed ID: 25388971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nutrient Sensing, Signaling and Ageing: The Role of IGF-1 and mTOR in Ageing and Age-Related Disease.
    Johnson SC
    Subcell Biochem; 2018; 90():49-97. PubMed ID: 30779006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IGF and mTOR pathway expression and in vitro effects of linsitinib and mTOR inhibitors in adrenocortical cancer.
    De Martino MC; van Koetsveld PM; Feelders RA; de Herder WW; Dogan F; Janssen JAMJL; Hofste Op Bruinink D; Pivonello C; Waaijers AM; Colao A; de Krijger RR; Pivonello R; Hofland LJ
    Endocrine; 2019 Jun; 64(3):673-684. PubMed ID: 30838516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin like growth factor-1-induced phosphorylation and altered distribution of tuberous sclerosis complex (TSC)1/TSC2 in C2C12 myotubes.
    Miyazaki M; McCarthy JJ; Esser KA
    FEBS J; 2010 May; 277(9):2180-91. PubMed ID: 20412061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ethyl pyruvate preserves IGF-I sensitivity toward mTOR substrates and protein synthesis in C2C12 myotubes.
    Frost RA; Pereyra E; Lang CH
    Endocrinology; 2011 Jan; 152(1):151-63. PubMed ID: 21106878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FM19G11: A new modulator of HIF that links mTOR activation with the DNA damage checkpoint pathways.
    Rodríguez-Jiménez FJ; Moreno-Manzano V; Mateos-Gregorio P; Royo I; Erceg S; Murguia JR; Sánchez-Puelles JM
    Cell Cycle; 2010 Jul; 9(14):2803-13. PubMed ID: 20676050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of intermittent and chronic calorie restriction on mammalian target of rapamycin (mTOR) and IGF-I signaling pathways in mammary fat pad tissues and mammary tumors.
    Dogan S; Johannsen AC; Grande JP; Cleary MP
    Nutr Cancer; 2011; 63(3):389-401. PubMed ID: 21462085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.